(Press-News.org) CINCINNATI - Researchers have successfully targeted an important molecular pathway that fuels a variety of cancers and related developmental syndromes called "Rasopathies."
Reporting their results Nov. 20 in Chemistry & Biology, scientists at Cincinnati Children's Hospital Medical Center say they identified a class of lead compounds that successfully recognize a key target in the Ras signaling pathway - opening the door to future development of therapies that could make treatments more effective with fewer side effects.
Although still in the early stages of the development process for a new drug, the researchers were encouraged by how effectively their lead compound (NSC-658497) targeted the key catalytic activation of Ras by an enzyme called SOS1. They also reported the lead compound was effective at blocking SOS1-mediated molecular signaling in the Ras pathway that causes rapid cell proliferation, tumor development and cancer.
"While Ras pathway activation is a dominant event happening in many diseases, so far, the immediate signaling module of the Ras pathway has been difficult to target. Most strategies for treatment have been geared toward hitting molecular effectors that are farther downstream," said Yi Zheng, PhD, principal author and director of Experimental Hematology and Cancer Biology at Cincinnati Children's.
"In this study, we have identified synthetic compounds that specifically recognize the catalytic pocket of SOS-1 and demonstrated that they are effective inhibitors of Ras signaling in cells," Zheng explained. "This establishes a novel targeting approach for cancers and Rasopatheis that is useful in developing therapeutics."
The Ras pathway is essential in the regulation of cells in the body - including differentiation, growth and cell senescence (when cells stop dividing). When dysregulation in the pathway occurs, as in the instance of genetic mutation, it prompts Ras signaling and cell growth to ramp up to harmful, disease-causing levels.
Rasopathies include a group of nine developmental syndromes that are caused by mutations in the Ras pathway (Noonan, LEOPARD, hereditary Gingival fibromatosis type 1, Capillary malformation-AV malformation, Neurofibromatosis type 1, Legius, Costello, Cardio-facio-cutaneous and automimmune lymphoproliferative), according to the Rasopathies Network. The syndromes produce a variety of unique symptoms but share common characteristics including facial features, cardiac defects, cutaneous abnormalities, neurocognitive delay and a predisposition to cancer.
Dysregulation of the Ras pathway (including its SOS1 catalytic activator) is also linked to a number of cancers such as breast, non-small-cell lung, pancreatic, prostate, cervical and leukemia.
Using virtual screening via computer and experimental laboratory screening, the scientists - including first author Chris Evelyn, PhD, a research fellow in the Zheng laboratory - initially tested 30,000 synthetic molecular compounds in a database maintained by the National Cancer Institute. They looked for the compounds' ability to dock with the catalytic site of SOS1. This led the researchers to initial identification of NSC-658497 and derivatives as lead candidates for development of a prospective therapeutic.
The researchers also tested NSC-658497 in cell lines of mouse fibroblasts and prostate cancer. These experiments showed the compound successfully blocked SOS1 to Ras signaling and the proliferation of cancer cells.
Zheng said among the next steps needed to develop NSC-658497 into a plausible therapeutic for clinical use is conducting further medicinal chemistry to transform the compound into a drug that can be administered to a living organism. This would allow the researchers to begin testing the inhibitor in mouse models of different Rasopathies and cancers.
One of the targeted approaches the scientists will explore is whether NSC-658497 might be most promising in individuals who have a subset of disease in which SOS1 is significantly overexpressed or mutated.
INFORMATION:
Funding support for the study came in part from the National Institutes of Health (NIH R01CA141341, R01CA150547, and P30DK090971).
About Cincinnati Children's
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2014 Best Children's Hospitals. It is also ranked in the top 10 for all 10 pediatric specialties. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at http://www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.
While investigating a rare genetic disorder, researchers at the University of California, San Diego School of Medicine have discovered that a ubiquitous signaling molecule is crucial to cellular reprogramming, a finding with significant implications for stem cell-based regenerative medicine, wound repair therapies and potential cancer treatments.
The findings are published in the Nov. 20 online issue of Cell Reports.
Karl Willert, PhD, assistant professor in the Department of Cellular and Molecular Medicine, and colleagues were attempting to use induced pluripotent ...
VIDEO:
Researchers at the Salk Institute explain how a new technology, called ReBiL, can spot protein interactions more accurately, providing a new tool for cancer and other drug diagnostics.
Click here for more information.
LA JOLLA--For decades, researchers have struggled to translate basic scientific discoveries about cancer into therapeutics that effectively--and with minimal side effects--shrink a tumor.
One avenue that may hold great potential is the development of ...
Researchers at the RIKEN Brain Science Institute in Japan have identified a key neuronal pathway that makes learning to avoid unpleasant situations possible. Published online in the November 20 issue of Neuron, the work shows that avoidance learning requires neural activity in the habenula representing changes in future expectations.
Learning to avoid threats is an essential survival skill for both humans and animals. To do so, animals must be able to predict a danger and then update their predictions based on their actions and new outcomes. Until now, the neural mechanisms ...
Scientists have created the largest-scale map to date of direct interactions between proteins encoded by the human genome and newly predicted dozens of genes to be involved in cancer.
The new "human interactome" map describes about 14,000 direct interactions between proteins. The interactome is the network formed by proteins and other cellular components that 'stick together.' The new map is over four times larger than any previous map of its kind, containing more high-quality interactions than have come from all previous studies put together.
CIFAR Senior Fellow ...
PHILADELPHIA - Human existence is basically circadian. Most of us wake in the morning, sleep in the evening, and eat in between. Body temperature, metabolism, and hormone levels all fluctuate throughout the day, and it is increasingly clear that disruption of those cycles can lead to metabolic disease.
Underlying these circadian rhythms is a molecular clock built of DNA-binding proteins called transcription factors. These proteins control the oscillation of circadian genes, serving as the wheels and springs of the clock itself. Yet not all circadian cycles peak at the ...
Harvard Stem Cell Institute scientists at Brigham and Women's Hospital have found the cellular origin of the tissue scarring caused by organ damage associated with diabetes, lung disease, high blood pressure, kidney disease, and other conditions. The buildup of scar tissue is known as fibrosis.
Fibrosis has a number of consequences, including inflammation, and reduced blood and oxygen delivery to the organ. In the long term, the scar tissue can lead to organ failure and eventually death. It is estimated that fibrosis contributes to 45 percent of all deaths in the developed ...
Liver cancer is one of the most frequent cancers in the world, and with the worst prognosis; according to the World Health Organisation (WHO), in 2012, 745,000 deaths were registered worldwide due to this cause, a figure only surpassed by lung cancer. The most aggressive and frequent form of liver cancer is hepato-cellular carcinoma (HCC); little is known about it and there are relatively few treatment options.
Researchers from the Spanish National Cancer Research Centre (CNIO), have produced the first mouse model that faithfully reproduces the steps of human HCC development, ...
Mouse cells and tissues created through nuclear transfer can be rejected by the body because of a previously unknown immune response to the cell's mitochondria, according to a study in mice by researchers at the Stanford University School of Medicine and colleagues in Germany, England and at MIT.
The findings reveal a likely, but surmountable, hurdle if such therapies are ever used in humans, the researchers said.
Stem cell therapies hold vast potential for repairing organs and treating disease. The greatest hope rests on the potential of pluripotent stem cells, which ...
A recently discovered protein complex known as STING plays a crucial role in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the body's innate immune system, according to two separate studies published in the Nov. 20 issue of the journal Immunity.
The studies, both from University of Chicago-based research teams, have major implications for the growing field of cancer immunotherapy. The findings show that when activated, the STING pathway triggers a natural immune response against the tumor. This includes production of chemical ...
Say you ignored one of those "this website is not trusted" warnings and it led to your computer being hacked. How would you react? Would you:
A. Quickly shut down your computer?
B. Yank out the cables?
C. Scream in cyber terror?
For a group of college students participating in a research experiment, all of the above were true. These gut reactions (and more) happened when a trio of Brigham Young University researchers simulated hacking into study participants' personal laptops.
"A lot of them freaked out--you could hear them audibly make noises from our observation ...
